Serplulimab combined with bevacizumab and chemotherapy as first-line treatment for recurrent or metastatic cervical cancer (ASTRUM-CC01): a phase II trial
BackgroundCervical cancer is one of the leading causes of cancer-related mortality among women worldwide. While immune checkpoint inhibitors combined with bevacizumab and chemotherapy are emerging as the standard first-line therapy for recurrent or met…